Table 2.
Univariate and multivariate analysis of risk factor for relapse‐free survival
| Log‐rank P | Adjusted HRa (95% CI) | Adjusted P | |
|---|---|---|---|
| Age | |||
| ≤45 y | .35 | Ref. | .33 |
| >45 y | 1.21 (0.82‐1.79) | ||
| Lymph node | |||
| Negative | <.001 | Ref. | <.001 |
| Positive | 3.25 (2.03‐5.18) | ||
| Size | |||
| ≤2 cm | <.001 | Ref. | <.001 |
| >2 cm | 2.50 (1.64‐3.82) | ||
| IHC‐based subtype | |||
| HR+HER2− | <.001 | Ref. | <.001 |
| HR+HER2+ | 2.52 (1.44‐4.42) | ||
| HR‐HER2− | 3.28 (1.99‐5.40) | ||
| HR‐HER2+ | 3.79 (2.27‐6.33) | ||
| Chemotherapy | |||
| No | .06 | Ref. | <.001 |
| Yes | 0.32 (0.18‐0.57) | ||
| GSTM1 | |||
| Null | .03 | Ref. | .02 |
| Present | 0.63 (0.42‐0.93) | ||
CI, confidence interval; HR, hazard ratio.
a
Adjusted for age, lymph node status, tumor size, immunohistochemistry‐based subtype, chemotherapy and GSTM1‐null/present polymorphism. HR with its 95% CI is calculated by the Cox risk proportion model.